Continuous Glucose Monitoring System (CGMS) is an advanced sensor technology used to track glucose level without pricking fingers. It is more effective & accessible for patients with type 2 diabetes (T2D). In it the glucose levels are taken from interstitial fluid. The system takes glucose measurements at regular intervals, 24 hours a day, and generates glucose direction & rate of change. The system involves reusable transmitters that provide real-time reading of glucose monitoring. It can help reduce the risk of hypoglycemia & hyperglycemia, whether users are on pump therapy or insulin injections. According to Centers for Disease Control and Prevention (CDC) report, in 2017, around 30.3 million people suffered from diabetes in the U.S. In September 2017, the FDA approved first CGMS that does not require fingerstick measurement calibration. Components of continuous glucose monitoring system include insulin pumps, transmitters & receivers, and sensors. The adult population makes more use of the system compared to children as the number of diabetic patients is more for adults.

Rise in adoption of the system, increase in prevalence of diabetes across the U.S., and rise in awareness among people are the key factors that is expected to drive the U.S. continuous glucose monitoring systems market during the forecast period. In addition, surge in need for hypoglycemic & hyperglycemic diagnosis and rise in demand for glucose level testing instantly is expected to boost the market in the coming years. Moreover, rise in opportunities in the U.S. with the surge in need for R & D by the key players is also expected to boost the growth of the market. However, expensive systems and stringent regulatory policies are the major restraints that are anticipated to hamper the growth of the market during the forecast period. In addition, increase in undiagnosed patient population and rise in product awareness is expected to provide numerous opportunities for the market in the coming years.

The market is segmented on the basis of component, age group, distribution channel, and end user. On the basis of component, it is categorized into insulin pumps, transmitters & receivers, and sensors. On the basis of age group, it is divided into adult and children. On the basis of distribution channel, it is segmented into retail pharmacy and online pharmacy. On the basis of end user, it is divided into hospitals, clinics, homecare diagnostics, and others.

Some of the major players operating in the U.S. continuous glucose monitoring systems (CGMS) market include Abbott Laboratories, Pfizer Inc., Baxter International Inc., Echo Therapeutics, Inc., Medtronic plc, F. Hoffmann-La Roche AG, Dexcom Inc., Animas Corporation, Novo Nordisk A/S, and GlySens Incorporated.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and market forecast estimations from 2019 to 2026, which assists to identify the prevailing U.S. continuous glucose monitoring systems (CGMS) market opportunities.
An in-depth market analysis includes study of the market and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate the U.S. plans.
A comprehensive analysis of the factors that drive and restrain the growth of the market is provided in the report.
The projections in this report are made by analyzing the current market trends and future market potential from 2019 to 2026, in terms of value.
An extensive analysis of the market provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the U.S. continuous glucose monitoring systems (CGMS) market.

KEY MARKET SEGMENTS

By Component

Insulin Pumps
Transmitters & Receivers
Sensors

By Age Group

Adult
Children

By Distribution Channel

Retail pharmacy
Online pharmacy

By End User

Hospitals
Clinics
Homecare Diagnostics
Others

FEATURED COMPANIES

Pfizer Inc

Abbott Laboratories

Baxter International Inc

Echo Therapeutics, Inc.

Medtronic Inc

F. Hoffmann-La Roche AG

TABLE OF CONTENT

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key Benefits
1.3. Key Market Segments
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition
3.2. Need for glucose monitoring systems

3.2.1. Diabetes–a pandemic

3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. U.S. healthcare expenditure on diabetes

3.3. Key Findings

3.3.1. Top investment pockets
3.3.2. Top winning strategies
3.3.3. Value Chain Analysis

3.4. Patent analysis

3.4.1. U.S. patent analysis, by market participant
3.4.2. Patent analysis, by year

3.5. Market Share Analysis, 2017 (Global)
3.6. FDA Government Regulations (21CFR820)

3.6.1. Objective and Scope of FDA 21CFR820

3.7. Reimbursement Scenario
3.8. Market dynamics

3.8.1. Drivers
3.8.2. Restraints
3.8.3. Opportunities
3.8.4. Impact analyses

CHAPTER 4: U.S. CONTINOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT

4.1. Overview

4.1.1. Market size and forecast

4.2. Sensors

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast

4.3. Transmitters & Receivers

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast

4.4. Integrated Insulin pumps

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast

CHAPTER 5: U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS

5.1. Overview

5.1.1. Market size and forecast

5.2. Adult Population (>14 years)

5.2.1. Market size and forecast

5.3. Children Population (≤14 years)

5.3.1. Market size and forecast

CHAPTER 6: U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Diagnostic centers/clinics

6.2.1. Market size and forecast

6.3. ICUs

6.3.1. Market size and forecast

6.4. Home Healthcare

6.4.1. Market size and forecast

CHAPTER 7: COMPANY PROFILES

7.1. Abbott Laboratories

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. A. Menarini Diagnostics S.r.l.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio

7.3. DexCom, Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. Echo Therapeutics, Inc.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Key strategic moves and developments

7.5. F. Hoffmann-La Roche Ltd.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. GlySens Incorporated

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Product portfolio
7.6.4. Key strategic moves and developments

7.7. Insulet Corporation

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product portfolio
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. Johnson & Johnson

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. Medtronic Plc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Senseonics Holdings, Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments